Faricimab
- TRADE NAME: Vabysmo (Genentech)
- INDICATIONS:
1. Neovascular (wet) age-related macular degeneration. 2. Diabetic macular edema.
- CLASS: Angiopoietin-2 inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 7.5 days (estimated)
FDA APPROVAL DATE: 01/28/2022
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
No adequate and well-controlled studies of faricimab administration in pregnant women..
Faricimab is contraindicated in patients with: ocular or periocular infections; active intraocular inflammation; a known hypersensitivity to faricimab or any of its excipients. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.
Page last updated 05/15/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
